Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PFE
STRONG BUYPfizer Inc. · Healthcare · United States · $138.4B · Avg Vol: $1.1B/d
COMPANY DESCRIPTION
Pfizer Inc. is a global pharmaceutical giant engaged in the research, development, manufacture, and sale of innovative medicines and vaccines across a wide array of therapeutic areas. The company's competitive moat stems from its robust R&D pipeline, extensive portfolio of blockbuster drugs, and formidable intellectual property protection, enabling it to deliver life-changing treatments worldwide. As a market leader, Pfizer leverages its global scale and distribution network to address significant unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 101.2B | 59.6B | 63.6B | 62.6B | -14.8% | 63.3B | 61.7B | 59.4B | -2.6% |
| EPS | 5.59 | 0.38 | 1.42 | 1.37 | -37.4% | 1.32 | 1.25 | 1.20 | -6.3% |
| Shares | 5.6B | 5.6B | 5.7B | 5.7B | +1.2% | 5.7B | — | — | — |
| Debt | 34.9B | 70.8B | 63.6B | 64.0B | 22.4% | 64.7B | — | — | — |
| Equity | 95.7B | 89.0B | 88.2B | 86.5B | -3.3% | — | — | — | — |
| Op CF | 29.3B | 8.7B | 12.7B | 11.7B | -26.3% | 12.0B | — | — | — |
| Inv CF | -15.8B | -32.3B | 2.7B | -1.4B | — | — | — | — | — |
| Fin CF | -14.8B | 26.1B | -17.1B | -10.3B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PFE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PFE | Pfizer Inc.(you) | $138.4B | 92 | STRONG BUY |
| GILD | Gilead Sciences, Inc. | $158.8B | 95 | STRONG BUY |
| GSK.L | GSK plc | $104.9B | 95 | STRONG BUY |
| AMG.DE | Amgen Inc. | $194.3B | 90 | STRONG BUY |
| SNY | Sanofi | $102.8B | 96 | STRONG BUY |
| BMY | Bristol-Myers Squibb Company | $117.5B | 99 | STRONG BUY |
| NVON.MX | Novo Nordisk A/S | $212.5B | 90 | STRONG BUY |
| MRK | Merck & Co., Inc. | $317.8B | 93 | STRONG BUY |
| RO.SW | Roche Holding AG | $336.1B | 93 | STRONG BUY |
| BAYN.DE | Bayer Aktiengesellschaft | $52.6B | 91 | STRONG BUY |
Peer medians: ROE 2.7% · P/E 22.9x · Gross margin 47.5%